The Public Repository of Xenografts enables discovery and randomized phase II-like trials in mice

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease

The public repository of xenografts enables discovery and randomized phase II-like trials in mice.

More than 90% of drugs with preclinical activity fail in human trials, largely due to insufficient efficacy. We hypothesized that adequately powered trials of patient-derived xenografts (PDX) in mice could efficiently define therapeutic activity across heterogeneous tumors. To address this hypothesis, we established a large, publicly available repository of well-characterized leukemia and lymphoma PDXs that undergo orthotopic engraftment, called the Public Repository of Xenografts (PRoXe). PRoXe includes all de-identified information relevant to the primary specimens and the PDXs derived from them. Using this repository, we demonstrate that large studies of acute leukemia PDXs that mimic human randomized clinical trials can characterize drug efficacy and generate transcriptional, functional, and proteomic biomarkers in both treatment-naive and relapsed/refractory disease

Measurement of the Tau topological branching ratios

Using data collected in the DELPHI detector at LEP-1, measurements of the inclusive T branching ratios for decay modes containing one, three, or five charged particles have been performed, giving the following results: B-1 equivalent to B T- (particle)(-) greater than or equal to0 pi (0) greater than or equal to 0K(0) v(T) (v(overbar)) = 85.316 +/- 0.093 +/- 0.049) %; B-3 equivalent to B(T- → 2h(-)h(+) greater than or equal to 0 pi (0) greater than or equal to0 pi (0) greater than or equal to 0K(0)z17) = (14.569 +/- 0.093 +/- 0.048)%; B-5 equivalent to B(T- → 3h(-)2h(+) greater than or equal to 0 pi (0) greater than or equal to 0K0(0)v(T)) = (0.115 +/- 0.013 +/- 0.006)%, where h is either a charged pi or K meson. The first quoted uncertainties are statistical and the second systematic